In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can

Executive Summary

Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.

You may also be interested in...



Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Can Bespoke Analytics Put A New Dazzle On Generics?

Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.

Can Bespoke Analytics Put New Dazzle On Copy Drugs?

Disruptions in the supply/demand configuration of generic drugs have plagued US health care for years. Picket Pharmaceuticals, a new start-up founded by a biostatistician veteran of Africa’s war on HIV, is using the illuminating powers of big data to stabilize the generics supply chain and find untapped areas of value among thousands of products in a business that remains a mystery to physicians, payers and patients alike.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel